2022 年 39 巻 4 号 p. 576-580
Dementia is one of the most important issues in the ageing world. Not only in Japan as a super aging society and whole developed nations with aging society, but also in the whole world. Disease–modifying therapies for Alzheimer disease (AD) have long been awaited for more than a quarter–century. One of the concerns for drug development is proper AD staging for clinical trials and difficulty for subject recruitment. As countermeasures for these obstacles, a concept of a preclinical stage Alzheimer disease and a trial–ready cohort have developed in several places. This article outlines a preclinical stage of AD and the Japanese trial–ready cohort (J–TRC).
